Finch Therapeutics
Microbiome restoration for C. difficile prevention
Somerville, MA, US
Finch Therapeutics is a biotechnology company that pioneered microbiome therapeutics and has since transitioned from drug development to an intellectual property (IP) holding and monetization entity.
How We Help
Problem Statement
To solve health conditions caused by the disruption of the microbiome in the human body by developing novel microbial therapies.
Core Technology
Human-First Discovery platform
Key Differentiators
Pioneered the microbiome therapeutics field.; Human-First Discovery platform leverages machine learning and clinical data.; Business model pivoted to IP holding and monetization.
Clinical Focus
Infectious Diseases; Neurology; Gastroenterology; Pediatrics
Company Info
- Business Model
- Licensing
- Total Funding
- 58,600,000
- Website
- www.finchtherapeutics.com/
Categories
Technologies
Clinical & IP
Clinical Validation
Phase 2 PRISM-EXT: 75% efficacy, 88.2% cumulative sustained cure. FDA Breakthrough Therapy and Fast Track designations. Phase 3 PRISM4 trial enrolling for C. difficile prevention.
MedStartr Index Score
?What do you think of Finch Therapeutics?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.